AvantGuard Secures $2.85 Million Seed Funding and $2.65 Million in NIH Grants to Advance Next-Generation Antimicrobial Solutions
AvantGuard, an Ithaca, New York–based biotechnology company developing next-generation antimicrobial solutions inspired by the human immune system, has bolstered its financial foundation through a combination of seed funding and substantial government research grants as it accelerates its mission to combat drug-resistant pathogens and expand its innovative product pipeline. The company’s proprietary technology, built around its Avantamine™ molecule, aims to deliver broad-spectrum antimicrobial protection without the resistance issues common to traditional antibiotics and disinfectants.
In May 2023, AvantGuard successfully closed a $2.85 million oversubscribed seed funding round that attracted backing from a consortium of investors with experience in early-stage technology and life sciences. The round included participation from Blue Ledge Capital, an investment firm focused on sustainable innovation; SOSV, a global early-stage venture capital firm and accelerator; LaunchNY, a nonprofit venture development organization supporting high-growth entrepreneurs in upstate New York; and Red Bear Angels, a group of angel investors committed to fueling regional startup growth. These investors contributed capital to help AvantGuard accelerate research and development of its antimicrobial chemistries, hire additional scientific talent, and expand the reach of its technology globally.
CEO Ted Eveleth described the seed funding as a pivotal milestone that enabled AvantGuard to bring its innovative platform closer to commercial readiness. The infusion of capital supported the company’s efforts to refine its chemistry formulations, deepen preclinical work and expand its team of world-class scientists dedicated to addressing urgent healthcare and public health challenges. The company’s solutions are designed to provide long-lasting protection against a wide range of pathogens, including viruses, bacteria, fungi and mold, across diverse settings such as healthcare facilities, industrial environments and everyday surfaces.
In addition to private investment, AvantGuard has secured significant research grants from the National Institutes of Health (NIH), further strengthening its financial position and validating its scientific approach. In November 2025, the company announced it had been awarded $2.65 million in NIH grants to advance its next-generation antimicrobial technologies across several key areas. These awards include a $2 million Phase IIB grant focused on developing long-lasting, non-corrosive surface disinfectants for healthcare and industrial settings, a $300,000 Phase I grant to support novel treatments for dermatophytosis (common fungal infections like ringworm and athlete’s foot), and a $350,000 Phase I grant to reduce infections in chronic diabetic foot ulcers—an area of significant clinical need.
The combined public and private funding positions AvantGuard to push forward on multiple fronts simultaneously. The NIH grants not only provide non-dilutive capital to advance preclinical development and regulatory planning but also reflect federal interest in solutions that address antimicrobial resistance—a critical global health threat. AvantGuard’s approach seeks to reshape infection prevention and treatment by offering safe, long-lasting protection that does not contribute to the emergence of resistant organisms, a major limitation of many current antibiotics and disinfectants.
AvantGuard’s strategic utilization of its seed capital has supported expansion into new areas of research and product design while strengthening its competitive position within the antimicrobial space. With additional capital from its seed round and over $7.5 million in grants funding, the company has advanced its product portfolio to include solutions such as AvantSept, AvantGel and Avant24, each targeting distinct markets ranging from high-touch healthcare surfaces to chronic wound care and everyday skin conditions.
The company’s trajectory from early seed funding to securing competitive research grants exemplifies its dual-track strategy: leveraging investor support to scale innovation while tapping public research dollars to validate and enhance its scientific platform. As AvantGuard continues to advance its antimicrobial technologies through formulation optimization and regulatory planning, its expanding financial backing reflects both investor and public sector confidence in its potential to make a lasting impact on infection prevention, wound management and microbial control at scale.
Overall, AvantGuard’s combined funding achievements underline sustained interest in antimicrobial innovation at a time when antibiotic resistance, surface contamination and chronic infections pose significant challenges to public health systems worldwide. Through strategic investment and government support, the company is well positioned to drive forward its long-term vision of safer, more effective antimicrobial solutions.
